The excitement around Moderna’s cancer vaccine is cooling. Here’s why.

The True Post icon

Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker’s experimental cancer treatment.

Source: MarketWatch

Share This Article
The newsroom of The True Post.
Leave a Comment